Dose intensification in hormone receptor-negative and/or human epidermal growth factor receptor 2-negative high-risk primary breast cancer

J Clin Oncol. 2012 Mar 1;30(7):758; author reply 759-60. doi: 10.1200/JCO.2011.39.7257. Epub 2011 Dec 27.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Breast Neoplasms / therapy*
  • Female
  • Hematopoietic Stem Cell Transplantation*
  • Humans

Substances

  • Antineoplastic Agents